Sac-TMT and Bevacizumab for Triple-Negative Breast Cancer Brain Tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Triple-negative breast cancer (hormone receptor negative and HER2 negative) with confirmed brain metastases (tumors in the brain) visible on MRI, at least 1 cm in size
- Good overall health status (ECOG score 0–2, meaning you can perform daily activities with minimal limitation)
- Normal or near-normal blood counts, liver function, kidney function, and heart function
- No prior treatment with bevacizumab (a blood vessel-blocking drug) or certain chemotherapy drugs, except in specific situations
- Life expectancy of at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (sacituzumab tirumotecan plus a third-generation EGFR inhibitor) with or without radiation therapy for advanced lung cancer that has spread to the brain after prior EGFR inhibitor treatment. The goal is to see if this combination can better control the cancer and improve outcomes for patients with brain metastases.
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
This study tests a combination of two drugs—Sacituzumab Tirumotecan (Sac-TMT) and an immunotherapy called KL-A167—given before surgery to shrink triple-negative breast tumors. It aims to improve outcomes for people with early-stage, high-risk breast cancer who have not yet had any treatment.
This trial tests a new sequence of drugs (Sac-TMT followed by capecitabine) versus capecitabine alone for people with early-stage, high-risk triple-negative breast cancer who do not have BRCA mutations. It aims to see if the added treatment helps prevent the cancer from coming back.
This trial tests a new drug called sacituzumab tirumotecan for people with triple-negative breast cancer that has spread to the brain. It may help shrink brain tumors and improve outcomes for those who have not responded to previous treatments.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Brain Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.